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Until recently, endocrine therapy for breast cancer was relatively simple. If the tumour expressed hormone receptors, regardless of
stage and age, tamoxifen was indicated. While this largely remains the case for premenopausal women, clinical trials in
postmenopausal women have broadened our choice to include one of three selective aromatase inhibitors (AIs), the nonsteroidal
agents anastrozole or letrozole and the steroidal agent exemestane. Comparative data concerning the efficacy, toxicity, tolerability
and cost of AI vs tamoxifen continues to evolve with over 40000 women slated to be involved in clinical trials. Currently, tamoxifen
remains an appropriate choice for adjuvant treatment, and will remain so unless a clear survival advantage emerges for adjuvant AI
therapy. However, anastrozole is widely seen as a useful alternative, with particular merit for patients prone to the development of
serious tamoxifen side effects. For endocrine therapy naı ¨ve advanced disease, several trials have provided evidence that a
nonsteroidal AI has replaced tamoxifen as optimal treatment. In the neoadjuvant setting, letrozole was also more effective than
tamoxifen, both in terms of response rates and the incidence of breast-conserving surgery, and so AI therefore also dominates this
evolving indication. The ongoing adjuvant clinical trials ask all the relevant questions regarding tamoxifen and AI in combination,
sequence and duration, except for 5 years of an AI vs a longer period. For both the advanced and early-stage disease, resistance
remains the key obstacle to overcome, and trials that combine endocrine agents with signal transduction inhibitors such as HER1 and
HER2 kinase inhibitors, farnesyl transferase inhibitors, mTOR inhibitors as well as COX2 inhibitors are being developed in a
concerted attempt to address this problem.
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Formulating a view on the relative merits of aromatase inhibitors
(AIs) and tamoxifen requires an examination of the available
evidence regarding four major issues – efficacy, toxicity, toler-
ability/quality of life and cost. Each of these factors must be
considered in the context of three major indications for endocrine
treatment – neoadjuvant, adjuvant and advanced disease. While
prevention is a fourth potential indication, there are no data yet
from prevention trials to discuss. However, the arimidex,
tamoxifen alone or in combination (ATAC) trial supports the
hypothesis that AIs have chemopreventive properties, and clinical
trials are now ongoing. For this review, ‘antioestrogen’ is
synonymous with tamoxifen, because the two other approved
antioestrogens either have no comparative data with AIs
(toremifene) or published comparisons with AIs were not
conducted in the first-line setting (fulvestrant).
What is first-line endocrine treatment for breast cancer?
First-line treatment for breast cancer is the easiest to define in
terms of a new diagnosis, whether a new primary or initial
systemic relapse. However, these events do not necessarily equate
to first-line endocrine therapy because the patient may have
already been exposed to raloxifene for osteoporosis or tamoxifen
for chemoprevention. There are unfortunately only limited data to
guide the clinical management of these patients. The recommen-
dation to use an adjuvant AI in selective oestrogen receptor
modulation (SERM)-exposed patients (Winer et al, 2002) stems
from advanced disease trials in which patients either relapsing on
or after tamoxifen therapy still have a reasonable chance of
responding to AIs (Smith and Dowsett, 2003). Similarly, a patient
with newly diagnosed hormone receptor-positive advanced disease
is highly likely to have already been treated with adjuvant
tamoxifen. If the relapse occurred on tamoxifen or within 6
months to 1 year of stopping tamoxifen, then the patient is
considered to be in a ‘second-line endocrine therapy’ category, and
the standard recommendation is an AI (Smith and Dowsett, 2003).
Patients who relapse after an interval of more than 1 year are
traditionally considered ‘first-line’ endocrine therapy candidates,
as the standard of care was to reintroduce tamoxifen therapy.
However, a recent large study demonstrated that this is a relatively
ineffective strategy, with an odds ratio favouring letrozole
treatment approaching 4 in this subgroup (Mouridsen et al,
2003). Perhaps, any patient who has completed a course of
adjuvant tamoxifen could really be considered to be a candidate
for second-line endocrine therapy upon relapse, regardless of how
long ago the exposure to tamoxifen was.
Antioestrogens and AIs have distinct mechanisms of action
Tamoxifen (antioestrogen) and aromatase inhibition (oestrogen
deprivation) are distinct approaches to oestrogen-dependent Received 14 August 2003; accepted 31 October 2003
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stem from these pharmacological fundamentals (Smith and
Dowsett, 2003). Unlike tamoxifen, AIs do not exhibit intrinsic
hormonal properties but affect oestrogen receptor (ER) function
indirectly by blocking the conversion of adrenal androgens to
oestrogen in the peripheral (i.e. nonovarian) tissues of postmeno-
pausal women, including the breast itself (Miller, 1991). When
deprived of oestrogens, ERs cannot bind to DNA, and are therefore
incapable of direct involvement in signalling. As a consequence,
the side effects of AIs stem from oestrogen deprivation – for
example, bone loss and atrophic vaginitis. In contrast, tamoxifen
has an intrinsic endocrine action by binding to ERs with high
affinity and activating ER dimerisation and DNA binding.
Tamoxifen-bound ER has altered gene-regulatory properties
referred to as SERM. In several normal tissues, tamoxifen-bound
ER is active and promotes, for example, bone mineralisation and
endometrial proliferation. In these instances, tamoxifen is acting as
an ‘oestrogen mimic’ or receptor agonist. As a consequence, the
serious side effects of tamoxifen are remarkably similar to
oestrogen replacement therapy (ERT) – venous thrombosis,
pulmonary embolus, stroke and endometrial cancer (ATAC,
2002). Like ERT, maintenance of bone mineral density is an
advantage of tamoxifen. These agonist effects may, however, limit
efficacy. Aromatase inhibitors do not interact with ER; so potential
resistance mechanisms related to SERM agonist effects on tumour
cells are avoided. Preclinical models with MCF7 xenografts
engineered to overexpress aromatase (Brodie et al, 2003), as well
as models of tamoxifen-dependent tumour growth (Gottardis and
Jordan, 1988), support this explanation for the therapeutic
advantage of AIs.
First-line therapy for advanced disease
This discussion will focus on anastrozole, letrozole and exemes-
tane. Fadrozole, a second-generation nonsteroidal AI, has been
shown to be equivalent to tamoxifen (Thurlimann et al, 1996) but
inferior to letrozole (Tominaga et al, 2003) in advanced breast
cancer, and will not be discussed further, as drug approval is
restricted to Japan.
Anastrozole
Anastrozole has been compared with tamoxifen as first-line
endocrine therapy in more than 1000 postmenopausal metastatic
breast cancer patients with either positive or unknown hormone
receptor status in two randomised double-blind trials. The study
from Europe (Bonneterre et al, 2000) showed similar time to
progression (TTP) and clinical benefit rates (defined as
CRþPRþdisease stabilisation of 424 weeks) in the anastrozole
and tamoxifen arms of the study (8.2 vs 8.3 months and 56.2 and
55.5%, respectively). In the North American study (Nabholtz et al,
2000), anastrozole was significantly superior to tamoxifen for both
TTP and clinical benefit rates (11.1 vs 5.6 months, P¼0.005 and
59.1 vs 45.6%, P¼0.0098, respectively). It is important to note that
there was a marked difference in the prevalence of known
receptor-positive patients between the two studies (45 and 89%,
respectively), potentially accounting for the differences observed.
The combined data analysis from the two studies showed
anastrozole to be equivalent to tamoxifen in TTP at a median
follow-up of 18.2 months (Bonneterre et al, 2001), but, in a
retrospective subgroup analysis, anastrozole was superior to
tamoxifen in the subgroup with known receptor-positive tumours
with respect to TTP (10.7 vs 6.4 months). In addition, although
anastrozole had similar objective response rates (29.0 vs 27.1%),
the clinical benefit rates were higher (57.1 vs 52.0%). It is therefore
reasonable to conclude that anastrozole is superior in terms of TTP
for patients with receptor-positive tumours. The controversy over
the interpretation of unplanned retrospective analyses used by
these investigators underscores the inappropriateness of including
patients with unknown receptor status in these studies. To avoid
this problem, patients without hormone receptor data are likely to
be excluded from future endocrine therapy trials.
Letrozole
Letrozole was compared with tamoxifen in a randomised trial of
907 patients, whose tumours were receptor positive or unknown
(Mouridsen et al, 2001). Recurrence during adjuvant antioestrogen
therapy or within the following 12 months or prior endocrine
therapy for advanced disease precluded enrollment, and only one
prior chemotherapy regimen for metastatic disease was allowed.
Letrozole treatment was found to be superior to tamoxifen, with a
median TTP of 41 weeks vs 26 weeks. The median time to
treatment failure, overall response rate and clinical benefit rate
were significantly better in favour of letrozole (40 vs 25 weeks; 30
vs 20%, P¼0.0006 and 49 vs 38%, P¼0.001). At a recent update
after a median of 32 months of follow-up, the superiority of
letrozole over tamoxifen in the TTP (median, 9.4 vs 6.0 months,
respectively; Po0.0001), time to treatment failure (median, 9 vs 5.7
months, respectively; Po0.0001), overall objective response rate
(32 vs 21%, respectively; P¼0.0002) and overall clinical benefit
were confirmed (Mouridsen et al, 2003). Interestingly, the total
duration of endocrine therapy (‘time to chemotherapy’) was
significantly longer for first-line letrozole than for first-line
tamoxifen (median, 16 months vs 9 months, P¼0.005). Similarly,
the time to worsening of Karnofsky performance score was also
significantly delayed with letrozole compared with tamoxifen,
underscoring the palliative benefits of a first-line AI approach.
Exemestane
Exemestane has been compared with tamoxifen in 117 previously
untreated breast cancers with either positive or unknown hormone
receptors in a randomised phase 2 EORTC study (Dirix et al,
2001). The overall response rate was better for exemestane than
tamoxifen (44.6 vs 14.3%). Time to progression has not been
analysed, as this is the primary end point of a Phase 3 extension of
this ongoing study.
Interpretation of the advanced disease data
The letrozole experience, by virtue of the consistent findings and
highly significant effects on the TTP and response rate, provided
the best evidence for the advantage of first-line AI treatment. These
advantages were independent of a number of baseline covariates,
including the site of disease, prior use of tamoxifen and known or
unknown hormone receptor status (Mouridsen et al, 2003). The
overall survival data from this trial have raised some interesting
issues regarding the sequencing of tamoxifen and letrozole.
Whereas women on letrozole had a clear trend towards improved
survival during the first 2 years, this survival benefit was ‘lost’ after
further follow-up (median survival 34 months with letrozole vs 30
months for tamoxifen). As a result, several parametric tests were
not significant when applied to the data (P¼0.53 log rank,
P¼0.079 Wilcoxon). However, the nonparametric Kolmogorov–
Smirnov-type test did indicate that the two survival curves were
significantly different in favour of letrozole between 6 and 20
months (P¼0.003). An obvious explanation for the apparently
‘temporary’ survival advantage for first-line letrozole is that cross-
over to letrozole also improved survival as second-line treatment
on the tamoxifen arm. The alternative hypothesis is that cross-over
to tamoxifen decreased the survival rate of patients who received
letrozole first. This possibility is not completely far-fetched.
Prolonged oestrogen deprivation causes oestrogen hypersensitivity
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tamoxifen as an agonist. Clearly, trials that investigate the
endocrine management of patients with AI-resistant advanced
disease are of major priority. The options now include tamoxifen,
fulvestrant (Howell, 2000) or switching from a nonsteroidal AI to
exemestane (Lonning et al, 2000). The data available on these
strategies are limited, but the response rates are generally less than
10%. In fact, perhaps the most active approach may be
pharmacological doses of oestrogen (Ingle, 2002), which would
concur with the apoptotic response of long-term oestrogen
deprived cells to the reintroduction of oestrogen (Song et al, 2001).
From the view of current practice, the higher response rate and
lower incidence of early progression when treating with letrozole
first translate into a quality of life benefit and staves off, the
moment palliative chemotherapy becomes necessary. This efficacy
distinction between AIs and tamoxifen is perhaps most important
for patients with disease involving vital organs, where disease
progression is most likely to trigger the use of palliative
chemotherapy. Aromatase inhibitors are quite active against
visceral disease and superior to tamoxifen in this regard
(Mouridsen et al, 2003). For patients with low volume disease
and low symptom burden, the order of treatment is arguably less
critical, because several endocrine agents are likely to be used in
the sequence, regardless of treatment response.
Aromatase inhibitor vs tamoxifen as adjuvant therapy
for breast cancer
Around 40000 patients are either scheduled to enroll or have
enrolled in adjuvant studies involving AIs, but the only study that
has been reported so far is the ATAC trial (ATAC, 2002). In all,
9366 patients were recruited, of whom 3125 were randomly
assigned anastrozole, 3116 tamoxifen and 3125 a combination of
both. A total of 7839 patients (84%) were known to be receptor-
positive. With a median follow-up of 33.3 months, the disease-free
survivals (defined as freedom from local recurrence, systemic
recurrence, contralateral breast cancer or death as first event) at 3
years were 89.4% on anastrozole and 87.4% on tamoxifen (hazard
ratio 0.83 (95% CI 0.71–0.96), P¼0.013). Results with the
combination were not significantly different from those with
tamoxifen alone (87.2%, 1.02 (0.89–1.18), P¼0.8). Improvements
in disease-free survival with anastrozole were only seen in the
receptor-positive population. The incidence of contralateral breast
cancer was also significantly lower with anastrozole than with
tamoxifen (odds ratio 0.42 (0.22–0.79), P¼0.007). After 47
months of follow-up and 1373 events, the DFS estimates were
86.9 and 84.5% for anastrozole and tamoxifen, respectively
(Buzdar, 2002). The actual events that make up these statistics
are provided in Table 1. The difference in DFS estimates was
slightly greater in the hormone-receptor positive subgroup (89.0 vs
86.1%). These differences remain modest in absolute terms and
persistent divergence of the curves with further follow-up, as well
as supportive data from other trials, will be very reassuring to
patients embarking on anastrozole as adjuvant treatment. With
each trial update, the risks and benefits will be weighed (Figure 1).
Only when the efficacy data become stronger, particularly with
respect to overall survival, or the differences in toxicity becomes
greater, are we likely to see a change in the ASCO technical review
on adjuvant AIs, which emphasises the strength of the tamoxifen
experience and the preliminary nature of the ATAC trial data
(Winer et al, 2002, 2003). This view was also endorsed by the
recent St Gallen Consensus Panel, which also recommended that
anastrozole be used only in postmenopausal women in whom
tamoxifen is contraindicated, or is not tolerated (Goldhirsch et al,
2003).
Neoadjuvant AI therapy
The results of a randomised comparison of letrozole and tamoxifen
as neoadjuvant therapy for postmenopausal women with Stage 2
and 3, hormone receptor-positive disease are noteworthy from a
number of standpoints (Eiermann et al, 2001). Letrozole produced
a higher clinical and radiological response rate than tamoxifen,
and also the incidence of breast-conserving surgery was superior
(all patients in the trial were considered ineligible for breast-
conserving surgery at baseline). This result therefore mirrors the
conclusion from the ATAC trial that a third-generation AI is more
effective than tamoxifen as treatment for primary breast cancer. If
neoadjuvant and adjuvant endocrine outcomes continue to be
concordant in this way, future novel endocrine strategies may
well use the neoadjuvant setting to establish essential preliminary
data to support a definitive large-scale adjuvant trial. Another
noteworthy aspect of the study concerned the opportunity to
conduct biomarker research to better understand the molecular
basis for the therapeutic response to endocrine agents. For
example, an analysis of trial outcomes according to HER1 (EGFR)
and HER2 (ErbB2) status demonstrated that the difference in the
effectiveness of letrozole and tamoxifen was particularly marked
for tumours that coexpressed ER and HER1 and/or HER2 (Ellis
et al, 2001). This finding has led to an effort to examine the
outcome of the ATAC study according to HER2 expression status
(Dowsett M, personal communication). Further biomarker re-
search has also shown that the cell cycle-related biomarker Ki67
is suppressed to a greater extent by letrozole than tamoxifen,
regardless of HER1 and HER2 expression status. This would
suggest that part of the superior efficacy associated with aromatase
inhibition is related to a greater inhibition of tumour proliferation
(Ellis et al, 2003). A significant obstacle to the routine adoption of
neoadjuvant endocrine therapy is the absence of a large validation
study in which the outcomes of patients who received neoadjuvant
AIs are directly compared with a group treated conventionally
(either with neoadjuvant chemotherapy or immediate surgery).








Deaths before recurrence 108 109 100
First event 413 472 488
Locoregional 84 101 107
Distant 195 222 246
CL (invasive) 20 35 30
CL (DCIS) 5 5 5
AN¼anastrozole; TAM¼tamoxifen; CL¼contralateral breast cancer; DCIS¼
ductal carcinoma in situ.
Tamoxifen Aromatase inhibitor
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Figure 1 Comparison of toxicities of AI vs tamoxifen from the
ATAC trial (CA¼cancer, DVT¼deep venous thrombosis, M/S¼
musculoskeletal).
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of research in this clinical context, as well as the inherent
advantages from a wider acceptance of a low-toxicity approach
to neoadjuvant treatment for older patients (Wong and Ellis,
2003).
Toxicity and tolerability
Differences in the side effect profile between tamoxifen and
anastrozole are marked, and arguably more likely to influence the
current prescribing practice than differences in efficacy. There is
no difference between anastrozole and tamoxifen in terms of
cataracts, ischaemic cardiovascular events, fatigue or asthenia,
mood disturbances and nausea and vomiting. However, anastro-
zole was associated with fewer endometrial cancers, vaginal
bleeding and discharge, cerebrovascular events, venous throm-
boembolic events and hot flushes. Tamoxifen caused fewer
musculoskeletal disorders and fractures. These data have led the
ASCO technical panel and the St Gallen Consensus panel to
emphasise that anastrozole might have an important role for those
at particular risk for severe tamoxifen side effects. On the other
hand, anastrozole should be prescribed with caution in patients
with osteopenia/osteoporosis. The increase in fracture risk
associated with anastrozole was evident even at the first analysis,
suggesting that the decline in bone strength may occur very rapidly
in some patients, perhaps even before major changes in bone
mineral density are detected. Arguably, all patients on adjuvant AI
therapy should receive vitamin D and calcium supplements, be
encouraged to exercise, and those with evidence for bone loss at
baseline should also receive an oral bisphosphonate, until practice
guidelines are established. The ASCO technical review and the St
Gallen Consensus Panel continue to emphasise the lack of safety
data regarding long-term oestrogen deprivation. For example, AIs
have been reported to alter cholesterol and lipoprotein metabolism
with potentially deleterious effects on cardiovascular health (Elisaf
et al, 2001). There are also concerns about the effects of long-term
oestrogen deprivation on memory and risk for dementia. Regions
of the brain such as the hippocampus and amygdala involved in
learning and memory are rich in ER, as oestrogen regulates
synapse formation and induces choline transferase and acetylcho-
linesterase, both critical to memory function (McEwen et al, 1997).
While tamoxifen has been implicated in decline in cognitive
function (Paganini-Hill and Clark, 2000), these data do not come
from double-blind randomised placebo-controlled trials, and so
the issue remains controversial. The positive influence of
oestrogen on the general health, vitality, mental health, depressive
symptoms, or sexual satisfaction has recently been seriously
questioned (Rossouw et al, 2002; Hays et al, 2003), and so, while
these issues need careful study, the potential of AIs to be unduly
toxic in the long run should not be overstated.
Quality of life
For metastatic breast cancer, balancing the toxicity-to-benefit ratio
of any treatment is vital in maintaining the quality of life in
otherwise incurable patients with a limited lifespan. In more than
900 patients enrolled in a multi-centre trial evaluating the efficacy
of letrozole compared to tamoxifen as first-line therapy in
metastatic breast cancer, letrozole offered a significantly longer
quality-adjusted survival than tamoxifen (mean duration for
TWiST or time without disease progression or toxicity was 10.1
months compared to 7.6 months for tamoxifen, P¼0.0004) (Irish
et al, 2002). Some have suggested that letrozole may be superior to
anastrozole in terms of gastrointestinal side effects, nausea and hot
flushes (Makris et al, 2002).
A European study that evaluated more than 500 women with
early breast cancer after 2–3 years of adjuvant tamoxifen found
that the adverse effects of tamoxifen therapy on quality of life may
be under-reported (Coombes et al, 2003). Using the FACT-ES
(Functional Assessment of Cancer Therapy or FACT-B, plus ES, an
18-item five-point endocrine subscale), eight symptoms that were
most problematic for 410% of the patients included: hot flushes,
night sweats, vaginal dryness, loss of interest in sex, weight gain,
bloatedness, breast sensitivity and mood swings (Fallowfield et al,
1999). However, results from the NSABP-P1 study showed that
there was no difference between tamoxifen and the placebo arms
with regard to depression, overall physical or mental quality of life
and weight gain, though those on the tamoxifen arm have more
vasomotor (hot flushes) and gynecological symptoms (vaginal
discharge) and difficulties in sexual functioning (Day, 2001; Day
et al, 2001). The final analysis of the effects of AIs on the quality of
life is still pending, but there are preliminary evidences that
anastrozole may cause a decline in sexual functioning compared to
tamoxifen (Fallowfield et al, 2002). While the ATAC trial showed
that postmenopausal symptoms such as hot flushes are fewer with
anastrozole, this is arguably offset by the higher prevalence of
musculoskeletal complaints, which may be quite marked in some
patients (Sainsbury, 2002).
Cost
Aromatase inhibitors cost several fold more than tamoxifen, a
critical issue for seniors without a prescription drug benefit or in
the context of government-run health-care systems. From a
pharmacoeconomics perspective, using a decision model (Markov
process) based on the UK National Health Service, letrozole is a
cost-effective alternative first-line therapy, compared with tamox-
ifen for postmenopausal women with advanced breast cancer,
achieving additional life-years at a mean incremental cost per life-
year gain of d2342 (Karnon and Jones, 2003). In another cost-
effectiveness analysis undertaken in Canada using a decision
model, quality-adjusted progression-free survivals between letro-
zole and anastrozole were comparable. Letrozole and anastrozole
cost Can$2883 and Can$2847 per patient, respectively, which were
marginally higher than tamoxifen at Can$ 2258 per patient. This
translated into an incremental cost over tamoxifen per quality-
adjusted progression-free year of $12,500 for letrozole and $19600
for anastrozole (Dranitsaris et al, 2003).
Conclusion and future directions
The third-generation AIs are a welcome additional option for the
endocrine therapy of hormone receptor-positive breast cancer in
postmenopausal women. While nonsteroidal AIs are more effective
than tamoxifen for the treatment of advanced disease, the absolute
reduction in relapse-free survival for adjuvant AIs over tamoxifen
is modest, and the results of several other large adjuvant trials are
currently pending. Since there is currently no evidence that the use
of an AI increases the number of patients cured of their disease, we
consider the impact of AI therapy to be relatively modest, at least
for the moment. The efficacy differences between tamoxifen and an
AI are likely to remain fairly narrow, because ultimately these
agents target the same signal transduction pathway. A critical
focus is, therefore, to develop and translate insights into the
molecular basis for endocrine therapy resistance. Neoadjuvant
studies are proving part of the key, since tissue is readily available
for genomic and proteomic approaches. Efforts should now also be
made to profile samples from advanced disease, in order to fully
understand the nature of the problem, since acquired resistance is
not adequately addressed in neoadjuvant studies. Combining AIs
and antioestrogens with a second signal transduction inhibitor to
prevent or even reverse endocrine therapy resistance is now under
investigation. The number of studies is rapidly expanding, and
involve a spectrum of agents including COX2 inhibitors (Harris
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Arteaga, 2001), farnesyl transferase inhibitors (Johnston et al,
2003) and mTOR inhibitors (Mita et al, 2003). Combining
endocrine therapy with the rational use of these agents may be
our best hope for more dramatic advances in the treatment of this
common disease.
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